A clinical study found increased exposure to several probe medicines. Different probes and endogenous markers helped distinguish enzyme inhibition from transporter explanations.
The measured pattern
Fenebrutinib increased exposures to midazolam, simvastatin, and rosuvastatin by roughly twofold to threefold in the reported study. Midazolam represented CYP3A, while the statins involved additional transport pathways.
Coproporphyrin biomarkers did not change, arguing against OATP1B inhibition as the main explanation. The authors instead favored CYP3A and BCRP effects, likely involving bioavailability.
Mechanistic inference has limits
No single probe uniquely resolves every elimination pathway. Unchanged biomarkers inform an explanation without proving that a pathway can never contribute under other conditions.
The study did not establish the degree of sedation associated with the midazolam increase or an effect shared by all benzodiazepines. Forensic interpretation should retain which measurement supports which pathway, the actual regimen, and uncertainty around individual response. A common exposure increase across drugs does not establish one identical mechanism for all of them.
Source paper
Original analysis of the supplied journal article, identified as PMC6977399.
Leave a Reply